ECSP951511A - NEUROPROTECTORS PHENOLS - Google Patents
NEUROPROTECTORS PHENOLSInfo
- Publication number
- ECSP951511A ECSP951511A ECSP951511A ECSP951511A EC SP951511 A ECSP951511 A EC SP951511A EC SP951511 A ECSP951511 A EC SP951511A EC SP951511 A ECSP951511 A EC SP951511A
- Authority
- EC
- Ecuador
- Prior art keywords
- hydrogen
- alzheimer
- disease
- pharmaceutically acceptable
- dementia
- Prior art date
Links
- 150000002989 phenols Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- -1 8-azabicyclo (3.2.1) octanyl Chemical group 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 230000001010 compromised effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El invento se refiere a compuestos de la fórmula (gráfico), o sus sales de adición de ácidos aceptables farmacéuticamente, en la que (a) R2 y R5 se toman separadamente y R1, R2, R3 y R4 son cada uno independientemente hidrógeno alquilo de (C1-C6), halo, CF3, OH y OR7 y R5, es metilo o etilo; o (b) R2 y R5 se toman juntos, formando un anillo de croman-4-pl; y R1, R3 y R4 son cada uno independientemente hidrógeno, alquilo de (C1-C6) halo, CF3, Oh y OR7; y R6 es un derivado de piperidinilo; pirrolidinilo u 8-azabiciclo (3.2.1) octanilo sustituido; con la salvedad de que (a) cuando R2 y R5 se tomen separadamente, al menos uno de R1, R2, R3 y R4 no sea hidrógeno; y (b) cuando R2 y R5 se tomen juntos, al menos uno de R1, R3 y R4 no sea hidrógeno; sus cpomposiciones farmacéuticas, y procedimientos de tratamiento de mamíferos que sufren de ataque súbito, trauma del cordón espinal, lesión cerebral traumática, demencia por infarto múltiple, enfermedades degenerativas del SNC, tales como enfermedad de Alzheimer, demencia senil del tipo de alzheimer, enfermedad de Huntington, enfermedad de Parkinson, epilepsia, esclerosis lateral amiotrofica dolor, demencia por SIDA, estados psicóticos,, adicciona fármacos, migraña, hipoglucemia, estados ansiolíticos, inconsistencia urinaria y un acontecimiento isquémico consecuencia de cirugía del SNC, cirugia a corazón abierto o cualquier procedimiento durante el cual la función del sistema cardiovascular está comprometida, con un compuesto de la fórmula (1) anterior o una de sus sales aceptables farmacéuticamente.The invention relates to compounds of the formula (graph), or their pharmaceutically acceptable acid addition salts, in which (a) R2 and R5 are taken separately and R1, R2, R3 and R4 are each independently hydrogen alkyl of (C1-C6), halo, CF3, OH and OR7 and R5, is methyl or ethyl; or (b) R2 and R5 are taken together, forming a chroman-4-pl ring; and R1, R3 and R4 are each independently hydrogen, (C1-C6) halo alkyl, CF3, Oh and OR7; and R6 is a derivative of piperidinyl; pyrrolidinyl or substituted 8-azabicyclo (3.2.1) octanyl; with the proviso that (a) when R2 and R5 are taken separately, at least one of R1, R2, R3 and R4 is not hydrogen; and (b) when R2 and R5 are taken together, at least one of R1, R3 and R4 is not hydrogen; its pharmaceutical compositions, and treatment procedures for mammals suffering from sudden attack, spinal cord trauma, traumatic brain injury, multiple infarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, Huntington's, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis pain, AIDS dementia, psychotic states, add drugs, migraine, hypoglycemia, anxiolytic states, urinary inconsistency and an ischemic event as a consequence of CNS surgery, open heart surgery or any procedure during which the function of the cardiovascular system is compromised, with a compound of the formula (1) above or one of its pharmaceutically acceptable salts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP951511 ECSP951511A (en) | 1995-08-18 | 1995-08-18 | NEUROPROTECTORS PHENOLS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP951511 ECSP951511A (en) | 1995-08-18 | 1995-08-18 | NEUROPROTECTORS PHENOLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP951511A true ECSP951511A (en) | 1997-07-28 |
Family
ID=42042155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP951511 ECSP951511A (en) | 1995-08-18 | 1995-08-18 | NEUROPROTECTORS PHENOLS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP951511A (en) |
-
1995
- 1995-08-18 EC ECSP951511 patent/ECSP951511A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4410320A1 (en) | PHENOLES NEUROPROTECTORS ANTIISCHEMICALS AND BLOCKERS OF AMINO ACID RECEPTORS EXCITORS DEFINED BY THE FORMULA | |
| CA2413424A1 (en) | Substituted bicyclic derivatives for the treatment of abnormal cell growth | |
| WO2004056786A3 (en) | Pyrimidine derivates for the treatment of abnormal cell growth | |
| YU30702A (en) | Novel benzimidazole derivatives useful as antiproliferate agents | |
| MY124390A (en) | Substituted bicyclic derivatives useful as anticancer agents | |
| BR0116085A (en) | Nmda receptor agonist pharmaceutical compositions | |
| CA2341690A1 (en) | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | |
| MY139357A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| CA2303801A1 (en) | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists | |
| AU5813898A (en) | Method for treatment of cns-involved lysosomal storage diseases | |
| CA2303764A1 (en) | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists | |
| DE69818678D1 (en) | (+) - NORCISAPRIDE APPLICABLE FOR 5-HT3 AND 5-HT4 CONDITIONAL DISEASES | |
| CA2326076A1 (en) | Novel macrolides | |
| IL147771A0 (en) | Novel 2-decarboxy-2-phosphinico prostaglandin f analogs | |
| ECSP951511A (en) | NEUROPROTECTORS PHENOLS | |
| CA2324343A1 (en) | C11 oxymyl and hydroxylamino prostaglandins useful as medicaments | |
| MY121206A (en) | Aminobenzamide compounds for the treatment of neurodegenerative disorders | |
| PT804186E (en) | ALCALOID DITERPENIC COMPOUNDS FROM INDOLE | |
| CA2376876A1 (en) | New isoindoloindolone derivatives, the process for preparing them and the pharmaceutical compounds that contain them | |
| CA2378628A1 (en) | New indenoindolone derivatives, the process for preparing them and the pharmaceutical compounds that contain them | |
| EP0473993A3 (en) | Novel peptide derivatives and their pharmaceutical use | |
| CA2270026A1 (en) | Substituted bicyclic derivatives for treating central nervous system disorders |